Proposed Aflibercept Biosimilar Shows Comparable Safety, Efficacy in Phase 3 AMD Trial
AVT06, a proposed biosimilar to aflibercept (Eylea; Regeneron Pharmaceuticals), demonstrated comparable efficacy, safety, and immunogenicity to the reference…